Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
  Report  
Delayed Quote. Delayed Nyse - 10/15 04:02:46 pm
85.04 USD   +0.41%
10/08MERCK AND : Cuts Emissions by 7%
DJ
10/08MERCK : Issues 2018/2019 Corporate Responsibility Report
BU
10/08MERCK AND COMPANY : Infos Business
CO
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/09/2019 10/10/2019 10/11/2019 10/14/2019 10/15/2019 Date
84.18(c) 83.76(c) 84.34(c) 84.69(c) 85.04(c) Last
4 519 505 8 426 533 5 967 463 5 545 251 4 979 292 Volume
+1.07% -0.50% +0.69% +0.41% +0.41% Change
More quotes
Financials (USD)
Sales 2019 45 924 M
EBIT 2019 15 669 M
Net income 2019 10 952 M
Debt 2019 19 843 M
Yield 2019 2,58%
Sales 2020 48 688 M
EBIT 2020 17 169 M
Net income 2020 12 633 M
Debt 2020 17 101 M
Yield 2020 2,79%
P/E ratio 2019 20,0x
P/E ratio 2020 16,8x
EV / Sales2019 5,17x
EV / Sales2020 4,82x
Capitalization 218 B
More Financials
Company
Merck and Company specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (73.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory,... 
Sector
Pharmaceuticals
Calendar
10/29 | 05:45amEarnings Release
More about the company
Surperformance© ratings of Merck and Company
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK AND COMPANY
10/15J&J's Courtroom Losses Pile Up -- WSJ
DJ
10/14Johnson & Johnson's Legal Challenges Mount
DJ
10/10Germany's Merck KGaA Acquires FloDesign Sonics
DJ
10/09Massive jury award against J&J highlights risks of its legal strategy
RE
10/08MERCK AND : Cuts Emissions by 7%
DJ
10/08MERCK : Issues 2018/2019 Corporate Responsibility Report
BU
10/084D Pharma Enters Vaccine Collaboration With Merck & Co.
DJ
10/08MERCK AND COMPANY : Infos Business
CO
10/07GLOBAL MARKETS LIVE : HSBC, PayPal, AMS, GE…
10/04Clarityne Market to See Major Growth by 2025 | Merck & Co, Bayer, Perrigo, Ap..
AQ
10/03MERCK AND : FDA Accepts Two Applications for Merck's DIFICID to Treat Children A..
AQ
10/03MERCK AND : KEYTRUDA Now Approved as Monotherapy in China for First-Line Treatme..
AQ
10/03PDS BIOTECHNOLOGY : Shares Up 38% on Merck Collaboration
DJ
10/03NetScientific Shares Jump as Portfolio Company PDS Collaborates With Merck & ..
DJ
10/02MERCK AND : Gets China OK for Keytruda as Monotherapy for First-Line NSCLC Treat..
DJ
More news
Analyst Recommendations on MERCK AND COMPANY
More recommendations
Sector news : Pharmaceuticals - NEC
02:48aDrug Firms In Talks To Settle Lawsuits -- WSJ
DJ
01:34aROCHE : Says Outlook Is Improving as Revenue Grows
DJ
10/15New Gilead Sciences CFO Expected to Pursue More Deals to Expand Portfolio
DJ
10/15Drug Distributors in Talks to Settle Opioid Litigation for $18 Billion -- 2nd..
DJ
10/15Drug Distributors in Talks to Settle Opioid Litigation for $18 Billion -- Upd..
DJ
More sector news : Pharmaceuticals - NEC
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Average target price 96,76  $
Last Close Price 85,04  $
Spread / Highest target 23,5%
Spread / Average Target 13,8%
Spread / Lowest Target 4,66%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY11.29%217 734
JOHNSON & JOHNSON1.29%350 587
ROCHE HOLDING AG19.25%248 542
PFIZER-16.38%201 883
NOVARTIS16.20%198 243
AMGEN5.13%122 735